X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

STHdhQ7/111

RRID:CVCL_DN41

Organism

Mus musculus

Comments

Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) [tsA58]. DT Created: 13-07-16; Last updated: 07-09-18; Version: 3

Proper Citation

Coriell Cat# CH00096, RRID:CVCL_DN41

Category

Transformed cell line DT Created: 13-07-16; Last updated: 07-09-18; Version: 3

Sex

DT Created: 13-07-16; Last updated: 07-09-18; Version: 3

Synonyms

ST HDH Q7/111, CHDI-90000072, CH00096 DT Created: 13-07-16, Last updated: 07-09-18, Version: 3

Vendor

Coriell

Cat Num

CH00096

Cross References

Coriell; CH00096 Wikidata; Q54970581 DT Created: 13-07-16; Last updated: 07-09-18; Version: 3

Hierarchy

DT Created: 13-07-16; Last updated: 07-09-18; Version: 3

Originate from Same Individual

DT Created: 13-07-16; Last updated: 07-09-18; Version: 3

Publications that use this research resource

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.

  • Di Pardo A
  • Sci Rep
  • 2017 Jul 13

Literature context:


Abstract:

Huntington's disease is characterized by a complex and heterogeneous pathogenic profile. Studies have shown that disturbance in lipid homeostasis may represent a critical determinant in the progression of several neurodegenerative disorders. The recognition of perturbed lipid metabolism is only recently becoming evident in HD. In order to provide more insight into the nature of such a perturbation and into the effect its modulation may have in HD pathology, we investigated the metabolism of Sphingosine-1-phosphate (S1P), one of the most important bioactive lipids, in both animal models and patient samples. Here, we demonstrated that S1P metabolism is significantly disrupted in HD even at early stage of the disease and importantly, we revealed that such a dysfunction represents a common denominator among multiple disease models ranging from cells to humans through mouse models. Interestingly, the in vitro anti-apoptotic and the pro-survival actions seen after modulation of S1P-metabolizing enzymes allows this axis to emerge as a new druggable target and unfolds its promising therapeutic potential for the development of more effective and targeted interventions against this incurable condition.

Funding information:
  • NIBIB NIH HHS - U01 EB021236(United States)
  • NIEHS NIH HHS - R01 ES016931()